YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

October 8, 2023

Primary Completion Date

April 27, 2025

Study Completion Date

April 27, 2025

Conditions
Atherosclerotic Cardiovascular Disease
Interventions
DRUG

YN001

In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.

DRUG

Placebo for YN001

The injection solution to mimic the YN001

DRUG

rosuvastatin calcium tablets

In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days

Trial Locations (6)

10000

Beijing Anzhen Hospital, Capital Medical University, Beijing

100034

Peking University first hospital, Beijing

130000

First Hospital of Jilin University, Changchun

Unknown

Renmin Hospital of Wuhan University, Wuhan

Zhongnan Hospital of Wuhan University, Wuhan

Renji Hospital Shanghai Jiaotong Unv. school of Medicine, Shanghai

All Listed Sponsors
lead

Beijing Inno Medicine Co., Ltd.

INDUSTRY

NCT06048588 - YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis | Biotech Hunter | Biotech Hunter